M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells.
Marta Coscia,Francesca Pantaleoni,Chiara Riganti,Candida Vitale,Micol Maria Rigoni,Silvia Peola,Barbara Castella,Myriam Foglietta,Valentina Griggio,Daniela Drandi,Marco Ladetto,Amalia Bosia,Mario Boccadoro,Massimo Massaia +13 more
TL;DR: Despite their more aggressive features, UM CLL B cells are more susceptible to spontaneous apoptosis and depend from environmental prosurvival signals, which can be exploited as a selective target of therapeutic interventions.
Journal ArticleDOI
Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation.
Enrico Maffini,Moreno Festuccia,Lucia Brunello,Mario Boccadoro,Luisa Giaccone,Benedetto Bruno +5 more
TL;DR: Given that some neurologic complications are not uncommonly diagnosed post mortem, their overall incidence is likely to be underestimated, and prompt recognition and timely treatment are of paramount importance to reduce the risk for transplantation-related death.
Journal ArticleDOI
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.
Heinz Ludwig,Michel Delforge,Thierry Facon,Hermann Einsele,Philippe Moreau,Hervé Avet-Loiseau,Mario Boccadoro,Roman Hájek,Mohamad Mohty,Michele Cavo,Meletios A. Dimopoulos,Jesús F. San-Miguel,Evangelos Terpos,Sonja Zweegman,Laurent Garderet,Maria-Victoria Mateos,Gordon Cook,Xavier Leleu,Hartmut Goldschmidt,Graham Jackson,Martin Kaiser,Katja Weisel,Niels W.C.J. van de Donk,Anders Waage,Meral Beksac,Ulf H. Mellqvist,Monika Engelhardt,Jo Caers,Christoph Driessen,Joan Bladé,Pieter Sonneveld +30 more
TL;DR: In this review, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome and present with very specific side effect profiles.
Journal ArticleDOI
Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)
Pere Gascón,Matti Aapro,Heinz Ludwig,Carsten Bokemeyer,Mario Boccadoro,Matthew Turner,Kris Denhaerynck,Karen MacDonald,Ivo Abraham +8 more
TL;DR: The clinical and safety outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) are well within the range of historically reported data for originator fil grastim underscoring the clinical effectiveness and safety of biosimilar FilgrastIM in daily clinical practice.
Journal ArticleDOI
Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy
Marta Coscia,Sara Mariani,Silvano Battaglio,C. Di Bello,F. Fiore,Myriam Foglietta,Alessandro Pileri,Mario Boccadoro,Massimo Massaia +8 more
TL;DR: This vaccine formulation can overcome Id-specific immune tolerance by inducing clinical responses that are worthy of further investigation and can overcome the residual tumor burden.